Protara Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Protara Therapeutics, Inc. (TARA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 1.10% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-09.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2022-03-09
- Protara Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was 1.10%, a 8.33% decline from fiscal 2020.
- Protara Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2020 was 1.20%, a 140.00% increase from fiscal 2019.
- Protara Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2019 was 0.50%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2021-12-31 | 1.10% 10-K · filed 2022-03-09 |
| 2020-12-31 | 1.20% 10-K · filed 2022-03-09 |
| 2019-12-31 | 0.50% 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |